Kelyniam Global Announces Q2 2026 Financial Results

Rhea-AI Summary

Kelyniam Global (OTC: KLYG) reported strong results for the six months ended June 30, 2026, with total revenue of $1,904,547, a 39.6% increase from $1,364,432 in the prior-year period. Gross profit rose 41.5% to $1,543,834.

Income from operations reached $177,970, compared with an operating loss of $(59,869) a year earlier, while EBITDA improved to $185,287 from a loss of $(52,474). According to Kelyniam, sales of its CustomizedBone™ regenerative implants grew more than 50% year over year, and the product remains the only cranial implant indicated for children as young as seven.

During the quarter, surgeons completed the first implantation of the FusionÔ PEEK + BCP regenerative implant, the third regenerative implant in Kelyniam’s portfolio. The company also generated revenue from a consulting and development agreement with another medical device company, aligning with its strategy to leverage its ISO-certified, FDA-cleared facility and regulatory expertise to attract long-term partners.

Positive

• Revenue +39.6% to $1,904,547 for six months ended June 30, 2026
• Gross profit +41.5% to $1,543,834 versus prior-year period
• Operating loss turned to profit: $177,970 vs. $(59,869) in 2025 period
• EBITDA turned positive: $185,287 vs. $(52,474) in prior-year period
• CustomizedBone™ sales grew more than 50% year over year
• First FusionÔ PEEK + BCP implant completed; third regenerative implant in portfolio

Negative

• None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CANTON, CT / ACCESS Newswire / August 11, 2026 / Kelyniam Global (OTCID:KLYG), a leader in custom cranial implants, today reported its financial results for the six months ended June 30, 2026. The company delivered excellent performance, with strong revenue growth and a clear improvement in profitability.

Financial Highlights for the Six Months Ended June 30, 2026 vs. 2025

• Total revenue reached $1,904,547, up 39.6% from $1,364,432 in the prior-year period.

• Gross profit increased 41.5% to $1,543,834, compared with $1,090,691 a year earlier.

• Income from operations was $177,970, reversing an operating loss of $(59,869) in the same period of 2025.

• EBITDA rose to $185,287 from a loss of $(52,474) in the prior-year period.

"We are very pleased with our strong start in 2026," said Ross Bjella, CEO. "These results reflect the hard work of our team and the growing demand for our regenerative product line. The successful first implantation of our FusionÔ PEEK + BCP implant marks the third regenerative implant in our portfolio. We believe regenerative medicine - where the implant supports the regrowth of the patient's own bone - is the future of neurosurgery, and we are deliberately building a pipeline of implant options around that belief."

Sales of CustomizedBone™ regenerative implants, licensed from Finceramica, grew more than 50% compared to the same period last year as surgeons gain experience and confidence with this technology. CustomizedBone™ is also the only cranial implant on the market indicated for children as young as seven years old.

During the quarter, a surgeon successfully implanted the first FusionÔ PEEK + Bicalcium Phosphate (BCP) implant. This innovative implant combines the strength of PEEK with the bone-integration properties of BCP. Both of Kelyniam's PEEK implants can be delivered overnight and can incorporate Kelyniam's patented integrated fixation system.

The company also generated revenue this year from a consulting and development agreement with another medical device company.

"Kelyniam is an ideal partner for early-stage or ex-U.S. medical device companies that need assistance with manufacturing or regulatory support," said Ross Bjella, CEO. "Our strategy is to leverage our expertise in design, manufacturing, and regulatory requirements to attract long-term partners, build a unique product line, and utilize the extra capacity in our ISO-certified and FDA-cleared facility."

About Kelyniam Global

About Kelyniam Global Kelyniam Global, Inc. specializes in the rapid production of custom prosthetic cranial implants using computer-aided design and computer-aided manufacturing of advanced medical-grade polymers. The company develops, manufactures, and distributes custom cranial and craniofacial implants for patients who need reconstruction. Kelyniam works closely with surgeons, health systems, and payors to support positive clinical and cost-of-care outcomes. For more information, visit www.Kelyniam.com.

Cautionary Note Regarding Forward-Looking Statements

As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially from those projected. These risks include changes in economic conditions, competitive factors, the company's ability to execute its plans, regulatory developments, and other risks described from time to time in the company's SEC reports.

Contact:

Ross Bjella
Rbjella@kelyniam.com

SOURCE Kelyniam Global Inc

View the original press release on ACCESS Newswire

FAQ

How did Kelyniam Global (KLYG) perform financially in Q2 2026 and the first half of 2026?

Kelyniam Global reported higher revenue and profitability for the six months ended June 30, 2026. According to Kelyniam, total revenue reached $1,904,547, up 39.6% year over year, with gross profit of $1,543,834 and income from operations of $177,970, turning prior losses into profit.

What revenue growth did Kelyniam Global (KLYG) report for the six months ended June 30, 2026?

Kelyniam Global reported revenue of $1,904,547 for the six months ended June 30, 2026. According to Kelyniam, this represents a 39.6% increase compared with $1,364,432 in the same period of 2025, reflecting increased demand, including growth in its regenerative implant product line.

Did Kelyniam Global (KLYG) return to profitability in its Q2 2026 year-to-date results?

Yes, Kelyniam Global reported positive operating income and EBITDA for the six months ended June 30, 2026. According to Kelyniam, income from operations was $177,970 versus a $(59,869) loss a year earlier, and EBITDA was $185,287 compared with $(52,474) in the prior-year period.

How are Kelyniam Global’s CustomizedBone™ regenerative implants performing in 2026?

Kelyniam Global reported strong growth for its CustomizedBone™ regenerative implants in 2026. According to Kelyniam, sales of these implants grew more than 50% year over year, and CustomizedBone™ is described as the only cranial implant indicated for children as young as seven years old.

What is Kelyniam Global’s FusionÔ PEEK + BCP implant and what milestone was reached in 2026?

FusionÔ PEEK + BCP is a regenerative cranial implant combining PEEK strength with bicalcium phosphate bone-integration properties. According to Kelyniam, a surgeon successfully completed the first implantation during the quarter, making it the third regenerative implant in the company’s product portfolio.

Does Kelyniam Global (KLYG) generate revenue beyond cranial implant sales in 2026?

Yes, Kelyniam Global generated additional revenue from services in 2026. According to Kelyniam, the company earned revenue from a consulting and development agreement with another medical device company, aligning with its strategy to leverage design, manufacturing, and regulatory expertise for long-term partnerships.

What strategic focus did Kelyniam Global (KLYG) highlight in its August 11, 2026 update?

Kelyniam Global highlighted a strategy centered on regenerative implants and partnering with other device companies. According to Kelyniam, it aims to build a unique product line and attract long-term partners by using its ISO-certified, FDA-cleared facility and expertise in design, manufacturing, and regulatory support.